You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020285030
Dec 20203405
Jan 202150011
Feb 202148015
Mar 202176015
Apr 202138025
May 202118026
Jun 20210016
Jul 20210019
Aug 20210017
Sep 20210014
Oct 202154020
Nov 202172025
Dec 202146012
Jan 20223708
Feb 202238012
Mar 202244012
Apr 202280011
May 202268019
Jun 20224609
Jul 202244017
Aug 202258011
Sep 202280011
Oct 20226408
Nov 202240011
Dec 20223209
Jan 20232004
Feb 20233207
Mar 20232203
Apr 20232409
May 20234405
Jun 20232808
Jul 20231004
Aug 20232403
Sep 20231403
Oct 202348017
Nov 20233404
Dec 202360010
Jan 2024202
Feb 20242801
Mar 20245400
Apr 20242002
May 20243208
Jun 20243201
Jul 20242003
Aug 20242803
Sep 20243204
Oct 20245003
Nov 20242403
Dec 20242808
Jan 202520017
Feb 2025804
Mar 2025001
Apr 2025005
May 2025002
Jun 2025104
Total20910536